Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
Open accessPublished version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It remains unclear if the long-term response is associated with the characteristics of CAR T cells in infusion products, hindering the identification of biomarkers to predict therapeutic outcomes. Here, we present 101,326 single-cell transcriptomes and surface protein landscape from the infusion products of 12 ALL patients. We observed substantial heterogeneity in the antigen-specific activation states, among which a deficiency of T helper 2 function was associated with CD19-positive relapse compared with durable responders (remission, >54 months). Proteomic data revealed that the frequency of early memory T cells, rather than activation or coinhibitory signatures, could distinguish the relapse. These findings were corroborated by independent functional profiling of 49 patients, and an integrative model was developed to predict the response. Our data unveil the molecular mechanisms that may inform strategies to boost specific T cell function to maintain long-term remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This analysis led to discovery of TH2 cell pathways and related genes as potential targets for maintaining 5-year remission following CAR T cell immunotherapy.”
From The technological landscape and applications of single-cell multi-omics (2023) · cites this paper as [166]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lack of TH2 functionality might be the cause of relapse in CAR-T treatment.”
From Single-cell sequencing to multi-omics: technologies and applications (2024) · cites this paper as [209]
In the citing paper
“Single-cell multi-omics has also been applied to assess chimeric antigen receptor (CAR) T cell therapy in acute lymphoblastic leukaemia, combining transcriptomics and proteomics data to determine the molecular basis of phenotypic differences between complete remission, non-responsive and relapsed individuals166.”
From The technological landscape and applications of single-cell multi-omics (2023) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174 · cited 3×
“All differential expression analyses were performed using Seurat v3 (48).”
MethodInfluentialUMAP: Uniform Manifold Approximation and Projection
McInnes, L., Healy, J., Saul, N., & Großberger, L. (2018) · Journal of Open Source Software · doi:10.21105/joss.00861 · Cited by 9,826
Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets.
Macosko, E. Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A. R., Kamitaki, N., Martersteck, E. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.002 · Cited by 7,110
UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction
McInnes, L., Healy, J., & Melville, J. (2018) · arXiv · doi:10.48550/arxiv.1802.03426 · Cited by 7,101 · cited 1×
“We used 20 canonical correlation analysis (CCA) dimensions and the default number of anchor neighbors and reduced the integrated mRNA data to two dimensions using UMAP for visualization (46).”
MethodScenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationCausal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citation
Research works printed but not linked: 1
- S. Schuster, M. R. Bishop, C. S. Tam, E. K. Waller, P. Borchmann, J. P. McGuirk, U. Jaeger, S. Jaglowski, C. Andreadis, J. R. Westin, I. Fleury, V. Bachanova, S. R. Foley, P. J. Ho, S. Mielke, J. M. Magenau, H. Holte, K. Van Besien, M. J. Kersten, T. Teshima, K. Tobinai, P. Corradini, O. Anak, L. B. Pacaud, C. del Corral, D. Pharma, R. Awasthi, F. Tai, G. Salles, R. T. Maziarz, Primary analysis of Juliet: A global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 130, 577 (2017).
Cited by
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
The technological landscape and applications of single-cell multi-omics
Baysoy, A., Bai, Z., Satija, R., & Fan, R. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00615-w · Cited by 1,037
Self-citationCAR-T cell manufacturing: Major process parameters and next-generation strategies
Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 303
FOXO1 is a master regulator of memory programming in CAR T cells
Doan, A. E., Mueller, K. P., Chen, A. Y., Rouin, G. T., Chen, Y., Daniel, B., Lattin, J., Markovska, M., Mozarsky, B., Arias-Umana, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07300-8 · Cited by 223
Self-citationSingle-cell sequencing to multi-omics: technologies and applications
Wu, X., Yang, X., Dai, Y., Zhao, Z., Zhu, J., Guo, H., & Yang, R. (2024) · Biomarker Research · doi:10.1186/s40364-024-00643-4 · Cited by 222
“…mechanisms of resistance to CAR-T therapy in acute lymphoblastic leukemia (ALL), Bai et al. integrated scRNA-seq and CITE-seq to compare responders and CD19-positive relapse patients, during which they confirmed lack of T H 2 functionality might be the cause of relapse in CAR-T treatment [209].”
MethodSelf-citation
Metadata
- Authors
- Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., Xiao, Y., Barrett, D. M., Myers, R. M., Grupp, S. A., June, C. H., Fan, R., Camara, P. G., & Melenhorst, J. J.
- Affiliations
- Yale University (US)
- University of Pennsylvania (US)
- Cleveland Clinic (US)
- Children's Hospital of Philadelphia (US)
- Parker Institute for Cancer Immunotherapy (US)
- Yale Cancer Center (US)
- Department of Genetics and Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Corresponding author
- Bai, Zhiliang
- Woodhouse, Steven
- Fan, Rong
- Melenhorst, J. Joseph
- ORCID
- Venue
- Science Advances
- Published
- 2022-06-10
- Volume
- 8
- Issue
- 23
- Pages
- eabj2820-eabj2820
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC9177075
- OpenAlex
- W4281666488
- Cited by
- 166
- References
- 50
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 36 · 2023: 36 · 2022: 13
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Yale University
- Entertainment Industry Foundation
- Li Ka Shing Foundation
- Society for Immunotherapy of Cancer
- Stand Up To Cancer
- National Cancer Institute (U01CA232361)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- acute lymphoblastic leukemia, CAR T-cell therapy, CD19, relapse, single-cell transcriptomics, T cell heterogeneity, co-inhibitory receptors, response prediction, biomarkers, T cell activation
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Recurrence, Immunotherapy, Adoptive, Antigens, CD19, Proteomics, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.